Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1986-6-2
|
pubmed:abstractText |
A phase I study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg-1 which was escalated up to 7 mg kg-1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg-1. In Schedule 2, the daily dose was started with 1.5 mg kg-1 which was escalated up to 8 mg kg-1 and given for 2-16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg-1 daily X 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg-1 of BHAC were administered the half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin's disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0736-0118
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
15-24
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3702507-Adult,
pubmed-meshheading:3702507-Aged,
pubmed-meshheading:3702507-Antineoplastic Agents,
pubmed-meshheading:3702507-Cytarabine,
pubmed-meshheading:3702507-Dose-Response Relationship, Drug,
pubmed-meshheading:3702507-Drug Evaluation,
pubmed-meshheading:3702507-Drug Tolerance,
pubmed-meshheading:3702507-Female,
pubmed-meshheading:3702507-Hematopoiesis,
pubmed-meshheading:3702507-Humans,
pubmed-meshheading:3702507-Kinetics,
pubmed-meshheading:3702507-Leukemia,
pubmed-meshheading:3702507-Lymphoma,
pubmed-meshheading:3702507-Male,
pubmed-meshheading:3702507-Metabolic Clearance Rate,
pubmed-meshheading:3702507-Middle Aged
|
pubmed:year |
1986
|
pubmed:articleTitle |
Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
|
pubmed:publicationType |
Journal Article
|